Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000308037 | SCV000399248 | likely benign | Brittle cornea syndrome 1 | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000443795 | SCV000531897 | benign | not specified | 2016-12-12 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Invitae | RCV002056509 | SCV002321583 | benign | not provided | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000308037 | SCV002514240 | benign | Brittle cornea syndrome 1 | 2021-12-05 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV002278428 | SCV002565381 | benign | Ehlers-Danlos syndrome | 2021-09-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002365374 | SCV002656669 | benign | Cardiovascular phenotype | 2019-01-09 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV000308037 | SCV002795934 | likely benign | Brittle cornea syndrome 1 | 2021-07-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV002056509 | SCV003917851 | likely benign | not provided | 2024-06-01 | criteria provided, single submitter | clinical testing | ZNF469: BP4, BS2 |